- Danaher ( NYSE: DHR ) projects its Q4 2022 non-GAAP core revenue growth will be in the high-single digits , an improvement of previously guidance of flat to a low-single digit percent decline.
- The life sciences company expects non-GAAP base business core revenue growth is expected to be in the high-single digit percent range, the same as in previous guidance.
- Rainer Blair said that the Danaher also experienced better than expected growth in the Cepheid molecular diagnostics business thanks more than $1B in respiratory testing revenue in Q4.
- Blair will discuss the company's Q4 performance in further detail Tuesday afternoon at the J.P. Morgan Healthcare Conference.
- Danaher was just downgraded at Credit Suisse earlier in January .
For further details see:
Danaher expects Q4 core revenue growth above previous guidance